anthrax immune globulin (Rx)

Brand and Other Names:Anthrasil
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

intravenous solution

  • 40-70mg/vial; variable fill volume per vial of total protein concentrate

Anthrax Exposure

Indicated for treatment of inhalational anthrax in combination with appropriate antibacterial drugs

≥17 years: 420 units (7 vials) IV; initiate IV infusion at 0.5 mL/min for 30 min; if tolerated, may increase infusion rate by 0.5 mL/min q30min; not to exceed 2 mL/min

Select initial dose based on clinical severity; severe cases may warrant use of 14 vials (840 units) in adults

Dosage Considerations

Effectiveness is based solely on efficacy studies conducted in animal models of inhalational anthrax

Does not cross the blood-brain barrier and does not prevent or treat meningitis

Does not have direct antibacterial activity

Adult dosage of 420 units (7 vials) contains up to 0.368 g protein per kg body weight

Adult dosage of 840 units (14 vials) contains up to 0.736 g protein per kg body weight

Dosage Forms & Strengths

intravenous solution

  • 40-70mg/vial; variable fill volume per vial of total protein concentrate

Anthrax Exposure

Indicated for treatment of inhalational anthrax in combination with appropriate antibacterial drugs

≤16 years: 60-420 units (1-7 vials) IV; initiate IV infusion at 0.01 mL/kg/min for 30 min; if tolerated, may increase infusion rate by 0.02 mL/kg/min q30min; not to exceed 0.04 mL/kg/min

Do not exceed adult infusion rate when initiating (ie, 0.5 mL/min) or for maximum infusion rate (ie, 2 mL/min)

Select initial dose based on clinical severity; severe cases may warrant use of 2-14 vials (based on weight) in pediatric patients weighing >5 kg

Vials needed by weight

  • <10 kg: 1 vial
  • 10 to <18 kg: 2 vials
  • 18 to <25 kg: 3 vials
  • 25 to <35 kg: 4 vials
  • 35 to <50 kg: 5 vials
  • 50 to <60 kg: 6 vials
  • ≥60 kg: 7 vials

Dosing Considerations

Effectiveness is based solely on efficacy studies conducted in animal models of inhalational anthrax

Does not cross the blood-brain barrier and does not prevent or treat meningitis

Does not have direct antibacterial activity

Protein load exposure to pediatric patients may range from 0.32 to 1.26 g per kg of body weight, depending on the weight-based pediatric dose

Next:

Interactions

Interaction Checker

and anthrax immune globulin

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (12)

                • adenovirus types 4 and 7 live, oral

                  anthrax immune globulin decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG.

                • BCG vaccine live

                  anthrax immune globulin decreases effects of BCG vaccine live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG.

                • influenza virus vaccine quadrivalent, intranasal

                  anthrax immune globulin decreases effects of influenza virus vaccine quadrivalent, intranasal by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG.

                • measles mumps and rubella vaccine, live

                  anthrax immune globulin decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG.

                • measles, mumps, rubella and varicella vaccine, live

                  anthrax immune globulin decreases effects of measles, mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG.

                • rotavirus oral vaccine, live

                  anthrax immune globulin decreases effects of rotavirus oral vaccine, live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG.

                • smallpox (vaccinia) vaccine, live

                  anthrax immune globulin decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG.

                • typhoid vaccine live

                  anthrax immune globulin decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG.

                • varicella virus vaccine live

                  anthrax immune globulin decreases effects of varicella virus vaccine live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG.

                • yellow fever vaccine

                  anthrax immune globulin decreases effects of yellow fever vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG.

                • zoster vaccine live

                  anthrax immune globulin decreases effects of zoster vaccine live by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Immune globulin administration may impair the efficacy of live attenuated vaccines. Defer vaccination with live virus vaccines until ~3 months after administration of anthrax IG. Revaccinate people who received anthrax IG shortly after live virus vaccination following 3 months after the administration of anthrax IG.

                • zoster vaccine recombinant

                  anthrax immune globulin decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant.

                Minor (0)

                  Previous
                  Next:

                  Adverse Effects

                  >10%

                  Headache (20.4%)

                  1-10%

                  Nausea (9.3%)

                  Infusion site pain (9.3%)

                  Infusion site swelling (7.4%)

                  Back pain (3.7%)

                  Previous
                  Next:

                  Warnings

                  Black Box Warnings

                  Falsely high blood glucose levels

                  • Maltose in immune globulin products, including anthrax immune globulin, may give falsely high blood glucose levels with some blood point-of-care glucose testing systems (eg, those based on the GDH-PQQ or glucose-dye-oxidoreductase methods), possibly resulting in inappropriate administration of insulin and life-threatening hypoglycemia
                  • To avoid interference by maltose, perform blood glucose measurements with a glucose-specific method (monitor and test strips)

                  Thrombosis

                  • May occur with immune globulin products
                  • Risk factors include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors
                  • Thrombosis may also occur in the absence of known risk factors
                  • For patients at risk of thrombosis, administer at the minimum infusion rate practicable
                  • Ensure adequate hydration in patients before administration
                  • Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity

                  Contraindications

                  History of anaphylaxis or prior severe systemic reaction associated with the parenteral administration of this or other human immune globulin preparations

                  IgA deficiency with antibodies against IgA and a history of IgA hypersensitivity, as it contains trace amounts of IgA (≤40 mcg/mL)

                  Cautions

                  Hypersensitivity reactions may occur

                  Contains maltose; may interfere with certain types of blood glucose monitoring systems (see Black Box Warnings)

                  Thrombosis may occur following treatment with immune globulin products (see Black Box Warnings)

                  Adverse reactions (eg, chills, fever, headache, nausea, vomiting) may be related to the rate of infusion; follow closely the recommended infusion rate

                  Hemolytic anemia and hemolysis may develop; anthrax immune globulin may contain blood group antibodies that may act as hemolysins and induce in vivo coating of red blood cells with immune globulin, causing a positive direct antiglobulin reaction and hemolysis

                  Aseptic meningitis syndrome, noncardiogenic pulmonary edema, and blood-borne infections may occur in association with administration of immune globulin products

                  Renal impairment

                  • Acute renal dysfunction, acute renal failure, osmotic nephropathy, acute tubular necrosis, proximal tubular nephropathy, and death may occur upon use of immune globulin intravenous products
                  • Caution with any degree of preexisting renal insufficiency and in patients at risk of developing renal insufficiency (including, but not limited to, those with diabetes mellitus, aged >65 yr, volume depletion, paraproteinemia, sepsis, and concurrent nephrotoxic drugs)
                  • Administer at the minimum rate of infusion if practicable and ensure that patients are not volume depleted before infusion; do not exceed the recommended infusion rate
                  • Assess renal function, including BUN and serum creatinine, before initiating and at appropriate intervals thereafter If renal function deteriorates, consider discontinuing
                  • Most cases of renal insufficiency following administration of immune globulin products have occurred in patients receiving total doses containing ≥400 mg/kg of sucrose; anthrax immune globulin does not contain sucrose
                  Previous
                  Next:

                  Pregnancy & Lactation

                  There are no human data to establish the presence or absence of associated risk during pregnancy or while breastfeeding

                  Pregnancy Categories

                  A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                  B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                  C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                  D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                  X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                  NA: Information not available.

                  Previous
                  Next:

                  Pharmacology

                  Mechanism of Action

                  Purified human intravenous immune globulin G (IgG) containing polyclonal antibodies that provides passive immunization that neutralizes anthrax toxin

                  Binds to protective antigen (PA) to prevent PA-mediated cellular entry of anthrax edema factor and lethal factor

                  Administered in combination with appropriate antibiotic therapy as the immune globulin by itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue to grow and produce anthrax toxins

                  It is prepared using plasma collected from healthy, screened donors who have been immunized with anthrax vaccine adsorbed (BioThrax)

                  Pharmacokinetics

                  The following parameters were measured at 3 different dosage levels (ie, 210 units, 420 units, and 840 units), respectively

                  AUC 0-4: 1031.8, 2176.7, and 4271 mU•d/mL

                  AUC 0-∞: 1277.5, 2536.7, 4788.8 mU•d/mL

                  Peak plasma concentration: 83, 156.4, and 316.7 mU/mL

                  Peak plasma time: 0.116, 0.12, and 0.169 days

                  Half-life: 24.3, 28.3, and 28 days

                  Vd: 5714.8, 6837.2, and 7238.2 mL

                  Clearance: 174.2, 169.7, and 188.6 mL/day

                  Previous
                  Next:

                  Administration

                  IV Preparation

                  Each vial has a minimum potency of ≥60 units/vial

                  Bring vials to room temperature

                  • Thaw frozen vials rapidly for immediate use by placing at room temperature for 1 hr followed by a water bath at 37°C (98.6°F) until thawed
                  • Alternatively, thaw vials by placing the required number of vials in a refrigerator at 2-8°C (36-46°F) until the vials are thawed (approximately 14 hr)
                  • Do not thaw in a microwave oven
                  • Do not refreeze vials
                  • Bring thawed vials to room temperature by letting sit on a bench for a few minutes prior to infusion

                  Inspect vials

                  • Inspect vials to ensure the product is fully thawed and free from discoloration and particulate matter
                  • Solution should be clear or slightly opalescent
                  • Do not use solutions that are cloudy, turbid, or have particulates
                  • Inspect vials to ensure there is no damage to the seal or vial
                  • If damaged, do not use and contact the manufacturer
                  • Gently swirl upright vials by hand to ensure uniformity
                  • Do not shake the vial during preparation to avoid foaming

                  IV infusion bag preparation

                  • Remove the protective caps from the product vials
                  • Wipe the exposed central portion of the rubber stopper with an isopropyl alcohol swab
                  • Withdraw the vial contents into a syringe, aseptically transfer into an appropriately sized IV bag, and label with the volume to be infused
                  • No further dilution is required
                  • Once punctured, use the vial contents to prepare the infusion bag and administer as soon as possible
                  • Contains no preservative

                  IV Administration

                  Administer in an IV line with constant infusion pump

                  Use of an in-line filter is optional

                  If adverse reactions occur (eg, flushing, headache, nausea, changes in pulse rate, or blood pressure), slow the rate of infusion or temporarily stop the infusion

                  Vials are for single use only

                  Discard any unused portion

                  Adult infusion rate

                  • Initial: 0.5 mL/min for 30 min
                  • If tolerated, may increase infusion rate by 0.5 mL/min q30min; not to exceed 2 mL/min

                  Pediatric infusion rate

                  • Initial: 0.01 mL/kg/min for 30 min
                  • If tolerated, may increase infusion rate by 0.02 mL/kg/min q30min; not to exceed 0.04 mL/kg/min
                  • Do not exceed adult infusion rate when initiating (ie, 0.5 mL/min) or for maximum infusion rate (ie, 2 mL/min)

                  Storage

                  Store frozen at or below -15°C (≤5°F) until required for use

                  Do not use after expiration date

                  Once punctured, use the vial contents to prepare the infusion bag and infuse as soon as possible

                  Contains no preservative

                  Do not refreeze, reuse, or save for future use

                  Discard any partially used vials

                  Previous
                  Next:

                  Images

                  No images available for this drug.
                  Previous
                  Next:

                  Patient Handout

                  A Patient Handout is not currently available for this monograph.
                  Previous
                  Next:

                  Formulary

                  FormularyPatient Discounts

                  Adding plans allows you to compare formulary status to other drugs in the same class.

                  To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                  Adding plans allows you to:

                  • View the formulary and any restrictions for each plan.
                  • Manage and view all your plans together – even plans in different states.
                  • Compare formulary status to other drugs in the same class.
                  • Access your plan list on any device – mobile or desktop.

                  The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                  Tier Description
                  1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                  2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                  3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                  4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  NC NOT COVERED – Drugs that are not covered by the plan.
                  Code Definition
                  PA Prior Authorization
                  Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                  QL Quantity Limits
                  Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                  ST Step Therapy
                  Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                  OR Other Restrictions
                  Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                  Additional Offers
                  Email to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  Email Forms to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  Previous
                  Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.